Pyrrolopyrimidine compounds as inhibitors of protein kinases
US10596174B2 · kind B2 · utility
3Cited by
14References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 17, 2017 |
| Grant date | Mar 24, 2020 |
| Priority date | — |
| Expiry date | Feb 17, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.